SMNR SEMNUR PHARMACEUTICALS revenue, earnings and financials
For the quarter ended June 30, 2026, SEMNUR PHARMACEUTICALS reported revenue of n/a, net income of −$4.35M and diluted EPS of −$0.02; for the fiscal year ended December 2025 revenue was n/a.
SMNR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$160M, net income −$160M (margin n/a), EPS −$0.78
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$4.69M, net income −$4.69M (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$3.17M, net income $633K (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$419K (margin n/a), EPS n/a
SMNR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.35M, EPS −$0.02
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.58M, EPS −$0.02
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$6.16M, EPS $0.00
- Quarter ended Sep 30, 2025: revenue n/a, net income −$153M, EPS −$0.76
- Quarter ended Jun 30, 2025: revenue n/a, net income −$999K, EPS −$0.01
- Quarter ended Mar 31, 2025: revenue n/a, net income −$665K, EPS −$0.01
- Quarter ended Dec 31, 2024: revenue n/a, net income −$167K, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.30M, EPS −$0.01
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.11M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.51M, EPS n/a
- Quarter ended Dec 31, 2023: revenue n/a, net income $633K, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income $631K, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income $458K, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$1.01M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$685K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income $307K, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$30.8K, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$11.3K, EPS −$0.01
SMNR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$5.87M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.89M, share buybacks $43.4M
- Fiscal year ended Dec 2023: operating cash flow −$633K, share buybacks $40.5M
- Fiscal year ended Dec 2022: operating cash flow −$426K, share buybacks n/a
SMNR balance sheet
- Jun 30, 2026: cash $39.0K, total assets $1.94M, total liabilities $31.6M, shareholders' equity −$29.7M
- Mar 31, 2026: cash $103K, total assets $1.97M, total liabilities $27.3M, shareholders' equity −$25.3M
- Dec 31, 2025: cash $20.0K, total assets $1.35M, total liabilities $22.1M, shareholders' equity −$20.8M
- Sep 30, 2025: cash $85.0K, total assets $774K, total liabilities $15.4M, shareholders' equity −$14.6M
- Jun 30, 2025: cash n/a, total assets $562K, total liabilities $11.2M, shareholders' equity −$44.4M
- Mar 31, 2025: cash n/a, total assets $9.15M, total liabilities $10.7M, shareholders' equity −$43.4M
- Dec 31, 2024: cash $12.0K, total assets $6.68M, total liabilities $49.5M, shareholders' equity −$42.8M
- Sep 30, 2024: cash n/a, total assets $8.92M, total liabilities $9.48M, shareholders' equity −$42.0M
Is SMNR profitable?
No. SEMNUR PHARMACEUTICALS lost $168M over the last four quarters.
What is SMNR's EPS?
Diluted earnings per share over the last four quarters were −$0.80; −$0.02 in the latest quarter.